Categories Earnings, Health Care

Intercept Pharmaceuticals reports mixed Q1 results

Intercept Pharmaceuticals (NASDAQ: ICPT) reported wider-than-expected losses in the first quarter of 2019, primarily due to higher R&D expenses related to NASH (nonalcoholic steatohepatitis) trials. Q1 net loss was $3.03 per share, wider than the Street’s projection of $2.57 per share.

Revenues for the quarter surged 45% year-over-year to $52.2 million. Analysts had, on an average, expected revenues of $51.71 million in Q1.

Image for representation (Photo by Drew Hays on Unsplash)

Q1 revenues included $51.8 million of Ocaliva net sales and approximately $0.4 million of licensing revenue.

Intercept shares have gained 21% in the trailing 52 weeks. However, the stock has been highly volatile this year and is currently down 12.5%.

Research and development expenses increased to $58.4 million in Q1, from $48.7 million in the prior year quarter.  Last month, the New York-based firm had announced that it’s NASH drug candidate obeticholic acid (OCA) showed better efficacy than placebo in the Phase 3 trials.

READ: WHAT IS NASH AND WHICH BIOTECH FIRMS ARE VYING FOR THE FIRST-MOVER STATUS

OCA is the most advanced drug candidate in the highly-competitive and potentially lucrative NASH space. Numerous other drugmakers including Pfizer (NYSE: PFE), Novartis (NYSE: NVS), Gilead Sciences (NASDAQ: GILD) and Allergan (NYSE: AGN) are also in the race to bring out NASH drugs.

Outlook

Based on the first quarter results, Intercept raised its 2019 Ocaliva net sales guidance range to between $235 million and $245 million. The company also updated its 2019 adjusted operating expenses guidance range to between $470 million and $500 million, in connection with the acceleration of our NASH NDA filing and launch preparation activities.  

Also Read:  Metlife Inc. (MET) Q2 2020 Earnings Conference Call Transcript

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Novavax (NVAX) stock tumbles despite beating bottom line estimates in Q2

After Novavax (NASDAQ: NVAX) reported its progress on developing the COVID-19 vaccine at the end of February, the shares of the company started trading in double-digits after a long time.

During tough times, Tilray (TLRY) looks overseas to achieve growth targets

Cannabis was recognized as an essential business in several markets when the shutdown came into effect, including Canada and some US states, at a time when its legalization is getting

Eastman Kodak (KODK) swings to a loss in Q2 2020; revenue drops 31%

Eastman Kodak (NYSE: KODK) reported a loss of $5 million on revenue of $213 million in the second quarter of 2020. The company earned $201 million in the prior-year quarter.

Top